Cancer drugs targeting signaling pathways have been hampered by problems of efficacy and tumor resistance. Will the next generation of kinase inhibitors fare better than the first? Ken Garber investigates.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
npj Breast Cancer Open Access 17 February 2022
-
Characterization of pathogenic germline mutations in human Protein Kinases
BMC Bioinformatics Open Access 05 July 2011
-
Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity
British Journal of Cancer Open Access 09 January 2007
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Daub H. et al. Nat. Rev. Drug Discov. 3, 1001–1010 (2004).
McInnes C. et al. Curr. Pharm. Des. 11, 1845–1863 (2005).
Branca, M. Nat. Biotechnol. 23, 639 (2005).
Manning G. et al. Science 298, 1912–1934 (2002).
Krause D.S. et al. New Engl. J. Med. 353, 172–187 (2005).
Lynch, T.J. et al. New Engl. J. Med. 350, 2129–2139 (2004).
Paez, J.G. et al., Science, 304, 1497–1500 (2004).
Neshat, M.S. et al., Proc Natl Acad Sci USA, 98: 10314–10319 (2001).
Podsypanina, K., et al., Proc Natl Acad Sci USA, 98: 10320–10325 (2001).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Nature Biotechnology 24, 119, (Feb 2006)
Nature Biotechnology 22, 15-18 (Jan 2004)
Nature Biotechnology 23, 267 (Mar 2005
Nature Biotechnology 22, 641 (Jun 2004)
Web links
Rights and permissions
About this article
Cite this article
Garber, K. The second wave in kinase cancer drugs. Nat Biotechnol 24, 127–130 (2006). https://doi.org/10.1038/nbt0206-127
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0206-127
This article is cited by
-
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
npj Breast Cancer (2022)
-
A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy
Hormones and Cancer (2017)
-
Pharmacophore modeling, 3D-QSAR, and molecular docking study on naphthyridine derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1
Medicinal Chemistry Research (2013)
-
Characterization of pathogenic germline mutations in human Protein Kinases
BMC Bioinformatics (2011)
-
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Nature Reviews Genetics (2010)